title: Decreased cytomegalovirus expression following proinflammatory cytokine treatment of primary human astrocytes.
abstract: Understanding the influence of immune effector mechanisms on CMV infection of the CNS may facilitate the development of immunotherapies for viral encephalitis. Using cultures of highly purified, fully permissive primary human astrocytes, proinflammatory cytokines, but not antiinflammatory cytokines or beta-chemokines, were found to inhibit CMV expression, DNA synthesis, and replication. Treatment with certain proinflammatory cytokines 24 h before CMV infection markedly suppressed viral expression in astrocytes. TNF-alpha, IL-1beta, and IFN-gamma all inhibited CMV expression (70 +/- 4.2%, 65 +/- 3.4%, and 82 +/- 3.6% inhibition of viral expression, respectively, n = 5). In contrast, no viral suppression was observed following IL-6 treatment. Suppressive activity was dependent on the addition of cytokines before CMV infection. Cytokine pretreatment did not affect CMV entry into primary astrocytes, and the observed cytokine-induced suppressive activity was not affected by the NO synthase inhibitor NG-monomethyl- -arginine (NGMA). Instead, the suppressive effect appeared to be mediated through a mechanism involving inhibition of CMV major immediate early promoter activity. These results support the hypothesis that proinflammatory cytokines possess anti-CMV activity in brain cells and may lead to new interventions for CMV encephalitis based upon immunotherapy.
authors.affiliation: Institute for Brain Disorders, Minneapolis Medical Research Foundation, Minneapolis, MN 55404, USA.
authors.forename: M C
authors.initials: MC
authors.lastname: Cheeran
authors.forename: S
authors.initials: S
authors.lastname: Hu
authors.forename: G
authors.initials: G
authors.lastname: Gekker
authors.forename: J R
authors.initials: JR
authors.lastname: Lokensgard
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology; D001253:Astrocytes / Q000276:immunology* / Q000378:metabolism / Q000821:virology*; D002478:Cells, Cultured; D016207:Cytokines / Q000494:pharmacology*; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology*; D004279:DNA, Viral / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004306:Dose-Response Relationship, Immunologic; D015967:Gene Expression Regulation, Viral / Q000276:immunology; D017781:Genes, Immediate-Early / Q000276:immunology; D006801:Humans; D017874:Immediate-Early Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D018836:Inflammation Mediators / Q000494:pharmacology*; D009569:Nitric Oxide / Q000502:physiology; D011401:Promoter Regions, Genetic / Q000276:immunology; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D013997:Time Factors; D014764:Viral Proteins; D014779:Virus Replication / Q000276:immunology
chemical_list: D000998:Antiviral Agents; D016207:Cytokines; D004279:DNA, Viral; C088645:IE1 protein, cytomegalovirus; D017874:Immediate-Early Proteins; D018836:Inflammation Mediators; D012333:RNA, Messenger; D014764:Viral Proteins; D009569:Nitric Oxide